Boston,  MA 
United States
  • Booth: 444

A paradigm shift in pediatric vision screening with blinq.

blinq., a paradigm shift in pediatric vision screening

Rebion manufactures innovative devices for definitively identifying life-altering diseases that manifest from functional impairments in the brain, most notably amblyopia (lazy eye).  Support the spirit of instrument-based vision screening initiatives with direct detection of amblyopia. 

Why is direct detection so important?

Clinical studies funded by NIH/NEI have shown that screening with blinq. is a dramatically more accurate approach to measuring for amblyopia than methods which merely collect data on amblyopic "risk factors."  Greater accuracy leads to a reduction in care costs while improving patient outcomes.

blinq. screening may be reimburseable under category III CPT code 07X6T "retinal polarization scan, ocular screening with on-site automated results, bilateral"

Brands: Rebion's "blinq." implements proprietary Neural Performance Scanning (NPS)

For technical assistance, please contact support.